← Research library

[Evaluation of efficiency and safety of adding neuromultivit to basic therapy of vertebrogenic radiculopathy].

Randomized study in people · 2017

What was studied
100 patients with L5–S1 vertebrogenic radiculopathy
Main finding
An open randomized trial reports greater improvement in pain and disability measures when Neuromultivit was added to basic therapy.

Reported findings and study design

100 L5–S1 radiculopathy patients in an open randomized add-on comparison: Neuromultivit plus basic care versus basic care.

Population or model 100 patients with L5–S1 vertebrogenic radiculopathy

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Pain/disability scalesAdd-on arm favoredp<0.05
Adverse-event spectrumDescribed as not significantly differentThe abstract nevertheless prints p<0.05; this inconsistency is not resolved

Neuromultivit is the studied preparation; this is class-level context under Binavit, not direct Binavit efficacy.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Open treatment and background therapy limit attribution. Short-term symptom improvement is not direct proof of nerve regeneration.
  • Neuromultivit is not Binavit; formulation, route and co-interventions require separate assessment.

Source details

Journal publication

Indexed citation and abstract checked; complete methods and risk-of-bias appraisal pending.

Sources checked

Citation

Randomized trialEnglish abstract

Khabirov FA, Khaibullin TI, Granatov EV. [Evaluation of efficiency and safety of adding neuromultivit to basic therapy of vertebrogenic radiculopathy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Study source ↗ · DOI 10.17116/jnevro201711710138-43 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards